PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

Summary

Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients. This study aims to identify safety and efficacy of prophylactic Tocilizumab treatment. In particular, to explore whether prophylactic Tocilizumab treatment can decrease the incidence and severity of CRS (and subsequent eventual neurotoxicity) following CAR-T-treatment.

Timeline

Start

2024-07-01

Primary completion

2026-12

Completion

2027-06

Drugs

Indications